S. Aureus Decolonization in HPN Patients.

• Status: Recruiting
• Trial end date: 2022-10-08
• Target enrollment: 0
• Participant gender: All

Summary

This trial focusses on identifying the most effective and safe long-term S. aureus carriage decolonization strategy in home parenteral nutrition patients. Half of the participants will receive a quick and short systemic antibiotic treatment combined with topical treatment, while the other half will receive only topical treatment on a periodic basis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Collaborators: Aalborg Universitetshospital; Aalborg University Hospital; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Rigshospitalet, Denmark; ZonMw: The Netherlands Organisation for Health Research and Development
• Treatments: Chlorhexidine; Chlorhexidine gluconate; Ciprofloxacin; Clarithromycin; Clindamycin; Clindamycin palmitate; Clindamycin phosphate; Doxycycline; Fusidic Acid; Mupirocin; Povidone-Iodine; Rifampin; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

Criteria

Inclusion Criteria:

• Patient is fully able to understand the nature of the proposed intervention.

• Written informed consent by the patient before entering the trial.

• Age ≥ 18 years.

• Estimated life expectancy ≥ 1 year.

• Patient colonized with S. aureus.

Exclusion Criteria:

• Cannot be expected to comply with the trial plan (substance abuse, mental condition).

• Pregnant or breastfeeding women.

• Continuous exposure to Methicillin-resistant S. aureus (MRSA; e.g. pig farmer).

• Allergy for chlorhexidine and betadine.

• No options for oral and/or topical antibiotics due to allergies.

• Active S. aureus infection.

• Currently on treatment with antibiotics active against S. aureus.

• Decolonization (including mupirocin) treatment in the previous two months.

• The presence of a nasal foreign body.

• Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) levels more than five times the upper limit of normal or liver failure.